http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2890238-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00 |
| filingDate | 2013-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cc8a37846c497f53bcdc163721dca5e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_701e82ebdfefa17a17343f6f613a93e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b753174312a4d2c24d9e480e55eb42a4 |
| publicationDate | 2014-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2890238-A1 |
| titleOfInvention | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| abstract | What is described is a method for treating an adverse side effect of MEK inhibitors by administering a pharmaceutical composition comprising IFN? to a cancer patient being treated by a MEK-inhibitor. The applicants discovered that MEK inhibitors produce unwanted visual disturbances as an adverse side effect in a significant fraction of cancer patients being treated by the drug, and that the side effect causes retinal detachment due to fluid accumulation in the eye. The method treats the retinal detachment caused by the anticancer therapeutic by providing a means of decreasing the amount of fluid present in the retina and/or subretinal space of the eye by administering the pharmaceutical composition comprising IFN? to the basolateral side of the retinal pigment epithelium, preferably by administering the pharmaceutical composition to the anterior surface of the eye in liquid droplets. |
| priorityDate | 2012-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 132.